RVO biomarkers can be established using an AI that draws out from intravenous fluorescein angiography and baseline characteristics.

KOCHI: 68-year-old Thankamma (name changed) from Ernakulam has been a diabetic patient for 15 years. As she did not manage ...

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, ...

Reports Q3 revenue $3.72B, consensus $3.67B. “Regeneron (REGN) had a strong third quarter marked by 11% revenue growth. We continued to ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Vaidehi S. Dedania, MD, from the New York University (NYU) Langone Health and the Grossman School of Medicine, spoke with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. She ...

Victoria Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency department can provide timely, accurate diagnosis while also benefiting the ...

THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024.